China Rejects Patent Application For Gilead’s Hepatitis C Drug
Reuters: China rejects patent linked to Gilead hepatitis C drug
“China has rejected a Gilead Sciences Inc. patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents for the controversial treatment…”
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.